Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899594 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin for Methamphetamine Addiction
A Early Phase 1 study of Methamphetamine Use Disorder, sponsored by Kevin Murnane.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06899594: Recruiting Early Phase 1 study of Methamphetamine Use Disorder, sponsored by Kevin Murnane.
NCT06899594 is a Early Phase 1 study of Methamphetamine Use Disorder that is actively recruiting participants, run by Kevin Murnane. The registered enrollment target is 20 participants, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899594, a Early Phase 1 study of Methamphetamine Use Disorder, is actively recruiting participants, sponsored by Kevin Murnane.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Primary Outcome
Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant).
Conditions Studied
Interventions
- DRUG Psilocybin 25 mg
Study Locations (1)
Louisiana
- LSU Health Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-04 |
| Est. Completion | 2027-03 |
| Phase | Early Phase 1 |
What NCT06899594 shows while recruiting
NCT06899594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 54-participant average among 12 other Methamphetamine Use Disorder trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Methamphetamine Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin 25 mg is the first listed.
NCT06899594 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06899594 about?
NCT06899594 is a clinical study titled "Psilocybin for Methamphetamine Addiction". The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on met...
What is the current status of trial NCT06899594?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-04. Estimated completion is 2027-03.
What conditions does trial NCT06899594 study?
This clinical trial studies the following conditions: Methamphetamine Use Disorder.
What interventions are being tested in trial NCT06899594?
The interventions under investigation include: Psilocybin 25 mg (DRUG).
Who is sponsoring clinical trial NCT06899594?
This trial is sponsored by Kevin Murnane, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899594 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06899594's enrollment target sits among peer trials
20 7th of 12 higher than 4 of 12 other Methamphetamine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Methamphetamine and Troriluzole
RECRUITING · Early Phase 1
-
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
RECRUITING · Phase 2
-
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
RECRUITING · NA
-
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
RECRUITING · NA
-
Non-Abstinence Outcomes in Methamphetamine Use Disorder
RECRUITING · NA
-
Methamphetamine Cue-reactivity
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI